Protein A resin is a critical tool in biopharmaceutical research and production, providing efficient and reliable antibody purification. This comprehensive guide aims to shed light on the properties, applications, and benefits of Protein A resin.
Protein A resin is typically composed of an agarose matrix to which Protein A, a bacterial protein derived from Staphylococcus aureus, is immobilized. The resin's high affinity for the Fc region of antibodies enables selective binding and purification of immunoglobulins, particularly monoclonal antibodies (mAbs).
In terms of applications, Protein A resin finds extensive use in the pharmaceutical industry for large-scale purification of therapeutic antibodies. Its exceptional binding capacity and robustness allow for efficient capture, resulting in high yields and purity of the desired antibody product. Moreover, Protein A resin can be employed in downstream processes, such as antibody characterization, affinity chromatography, and analysis of antibody-antigen interactions.
The benefits of Protein A resin include its specificity, reproducibility, and scalability. It offers a streamlined purification process, reducing time and cost in biopharmaceutical manufacturing. Additionally, Protein A resin can be regenerated and reused, making it a cost-effective option.
In conclusion, Protein A resin is a versatile and powerful tool for antibody purification, with wide-ranging applications in biopharmaceutical research and production. Understanding its properties, applications, and benefits is essential for researchers and industry professionals aiming to achieve efficient and high-quality antibody purification.
Read More:
The global Protein A Resin Market research report, published by Value Market Research, is designed to offer various market framework such as market size, portion, trends, growth path, value and factors that impact the current market dynamics over the forecast period 2021-2027.
Most importantly, this report also provides the latest significant strategies adopted by major players along with their market share.The report also covers detailed competitive landscape including company profiles of key players operating in the global market.
The key players in the protein A resin market includes Agarose Bead Technologies (ABT), Bio-Rad Laboratories, Inc., Danaher Corporation, EMD Millipore, Expedeon Ltd, GE Healthcare, GenScript Corporation, Novasep, Purolite Life Sciences, Repligen, Sigma-Aldrich Corporation, Takara Bio Inc., Thermo Fisher Scientific and Tosoh Bioscience LLC among others.
An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.Get more information on "Global Protein A Resin Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/protein-a-resin-market/download-sampleMarket DynamicsThe market is expected to witness substantial growth owing to growing demand for monoclonal antibodies.
In addition to this, the ongoing trend of outsourcing research activities resulting in higher demand for contract research organization is also contributing to the growth of protein A resin market.
Despite this, the high cost of Protein A resin may hinder market growth.This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis.
The growth in this market is mainly driven by the growing demand for disposable pre-packed columns, increasing demand for therapeutic antibodies, and the increasing pharmaceutical R spending are expected to drive the growth of this market during the forecast period.
[140 Pages Report] The protein A resin market is expected to reach USD 1.9 billion by 2025 from USD 1.1 billion in 2020, at a CAGR of 11.4% during the forecast period.The study involved four major activities in estimating the current size for the protein A resin market.
The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.Market DynamicsGrowing demand for disposable pre-packed columnsIncreasing demand for therapeutic antibodiesIncreasing pharmaceutical R spendingCOVID-19 Impact on the Protein A Resin MarketFor the past 30 years, monoclonal antibodies have transformed the way we treat various diseases—they have proven to be more effective, better tolerated, and easier to deliver than other treatments.
Researchers are optimistic that monoclonal antibodies could help prevent and treat early infections of COVID-19.
One of these is adalimumab, used to treat arthritis and Crohn’s disease; the University of Oxford recently launched a trial to look at its potential to treat people in care homes, funded by the COVID-19 Therapeutics Accelerator.
Eli Lilly and Company (US), in collaboration with AbCellera (Canada), launched the first human study of a potential COVID-19 antibody treatment in June 2020.Get a sample PDF copy of the Report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=19196962Chromatography is an essential step in the purification of monoclonal antibodies (mAbs).
